98%
921
2 minutes
20
Curative treatment for head and neck cancers (HNC) typically involves a multidisciplinary approach, combining surgery, chemotherapy, and radiotherapy. Although a curative outcome is achieved in approximately 50 % of cases, long-term survivors frequently experience significant treatment-related sequelae, which substantially diminish both quality of life and overall life expectancy. These toxicities commonly manifest in clusters and encompass both local and systemic symptoms, the latter including asthenia, fatigue, sleep disturbances, thermoregulatory dysfunction, pain, gastrointestinal and neurocognitive impairments, and mood disorders. Emerging evidence over the past decades has increasingly implicated systemic inflammation as a central driver of these late effects. In this review, we summarize current evidence on late systemic toxicity in HNC survivors and examine the intricate relationship between systemic inflammation and said toxicity. Importantly, we highlight the need to recognize these symptoms not as isolated entities, but as components of an inflammatory symptom cluster, thus necessitating a therapeutic approach that targets underlying inflammation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.critrevonc.2025.104781 | DOI Listing |
Geroscience
September 2025
NUS Bia-Echo Asia Centre for Reproductive Longevity and Equality, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
In the past century, the human Lifespan has doubled. However, this is not equivalent to Healthspan which refers to the number of years spent healthy and free from disease. Women have an additional level of complexity on the path to optimal healthspan where health resilience dramatically decreases following menopause and this is due to their ovaries aging by midlife.
View Article and Find Full Text PDFBull Cancer
September 2025
Département d'oncologie médicale, centre Léon-Bérard (CLB-UNICANCER), université Claude-Bernard (UCB Lyon 1), Lyon, France. Electronic address:
Granulosa cell tumors (GCTs) are rare ovarian neoplasms, accounting for 2-5% of all ovarian cancers. Two histological types have been described: juvenile (JGCT) and adult (AGCT), the latter accounting for around 95% of the GCTs. AGCTs are mostly diagnosed at an early stage and commonly have a good prognosis.
View Article and Find Full Text PDFBMJ Open
September 2025
Erasmus Universiteit Rotterdam, Erasmus School of Health Policy and Management, Rotterdam, The Netherlands.
Introduction: Non-communicable diseases (NCDs) are a leading cause of global mortality, disproportionately affecting low and middle-income countries (LMICs). Physical inactivity, a key contributor to NCDs, is prevalent worldwide despite evidence supporting the health benefits of physical activity (PA). Cities, while often associated with barriers to PA, also present unique opportunities to enhance PA through systemic, context-sensitive interventions or so-called actions.
View Article and Find Full Text PDFExp Physiol
September 2025
Unit of Cardiac Physiology, Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre, 3.24 Core Technology Facility, University of Manchester, Manchester, UK.
The phosphodiesterase-5 inhibitor sildenafil suppresses ventricular arrhythmias in a sheep model of drug-induced long QT. In that study, ventricular arrhythmias were abolished by reducing premature ventricular complexes (PVCs) and delaying PVC onset, thus preventing 'R-on-T' ventricular tachycardia. Evidence for effects in humans with arrhythmias is lacking.
View Article and Find Full Text PDFPol Merkur Lekarski
September 2025
LLC "ECOFARM", KYIV, UKRAINE.
Objective: Aim: To consider the specific activity of drops and suppositories of PROTEFLAZID® at the stage of preclinical study, to assess the effectiveness and safety of use in clinical practice in papillomavirus-associated diseases of the female reproductive system..
Patients And Methods: Materials and Methods: Analysis of scientific publications on the treatment of palilomavirus infection with PROTEFLAZID® in women over the past decade.